Comerford E, Norcross L, Sasane M, Zheng Y, Gnanasakthy A. Patient-reported outcome (PRO) data in oncology NDAs approved by the FDA (2018–2021): a review of criticism and concerns in comments from regulators. Poster presented at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference; April 5, 2024. Orlando, FL. [abstract] J Natl Compr Canc Netw. 2024 Apr 5; 22(2.5). doi: 10.6004/jnccn.2023.7146
Jeuland M, McClatchey M, Patil SR, Pattanayak SK, Poulos CM, Chen Yang J. Do decentralized community treatment plants provide clean water? Evidence from rural Andhra Pradesh, India. Land Econ. 2021 May;97(2).
Ayad M, Karanth S, Narat M, Luther K, Patel B. Outcomes of creating an automated repeat lactate rule in sepsis patients with lactate levels ≥2. Poster presented at the 2019 Institute for Healthcare Improvement (IHI) Scientific Symposium; December 2019. Orlando, FL. [abstract] BMJ Open Qual. 2019; 8(Suppl 2):A39. doi: 10.1136/bmjoq-2019-ihi.23
Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis. Poster presented at the Australasian College of Dermatologists 50th Annual Scientific Meeting; May 2017. Sydney, Australia. [abstract] Australas J Dermatol. 2017 May; 58(S1):106-7. Previously presented at the 2017 American Academy of Dermatology Annual Meeting. doi: 10.1111/ajd.21_12652
Liu X, Sarr M, Swanson T. Resistance to the regulation of common water resources in rural Tunisia. Land Econ. 2015 Aug;91:435-59. doi: 10.3368/le.91.3.435
Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.
Von Scheele BG, Martin RD, Gilsenan AW, Ceberg J, Andrews EB, Masica D, Alvegård T. The European postmarketing adult osteosarcoma surveillance study characteristics of patients: a preliminary report. Acta Orthop. 2009;80:67-74.
Mansfield CA, Phaneuf D, Johnson FR, Yang J, Beach RH. Preferences for public lands management under competing uses: the case of Yellowstone National Park. Land Econ. 2008 May 1;84(2):282-305.
Mansfield CA, Van Houtven GL, Huber J. Compensating for public harms: why public goods are preferred to money. Land Econ. 2002;78(3):368-89.